Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M601805200 on March 16, 2006

J. Biol. Chem., Vol. 281, Issue 19, 13317-13323, May 12, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/19/13317    most recent
M601805200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, D. P.
Right arrow Articles by Peek, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, D. P.
Right arrow Articles by Peek, R. M., Jr.
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Role of Decay-accelerating Factor as a Receptor for Helicobacter pylori and a Mediator of Gastric Inflammation*{diamondsuit}

Daniel P. O'Brien{ddagger}, Dawn A. Israel{ddagger}, Uma Krishna{ddagger}, Judith Romero-Gallo{ddagger}, John Nedrud§, M. Edward Medof§, Feng Lin§, Raymond Redline§, Douglas M. Lublin, Bogdan J. Nowicki||, Aime T. Franco{ddagger}, Seth Ogden{ddagger}, Amanda D. Williams{ddagger}, D. Brent Polk{ddagger}, and Richard M. Peek, Jr.{ddagger}**1

From the {ddagger}Division of Gastroenterology, Departments of Medicine, Pediatrics, and Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2279, the §Institute of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, the Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110, the ||Departments of Obstetrics & Gynecology and Biomedical Sciences and Division of Microbial Pathogenesis and Immune Response, Meharry Medical Center, Nashville, Tennessee 37208, and the **Department of Veterans Affairs Medical Center, Nashville, Tennessee 37212

Received for publication, February 24, 2006


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Persistent gastritis induced by Helicobacter pylori is the strongest known risk factor for peptic ulcer disease and distal gastric adenocarcinoma, a process for which adherence of H. pylori to gastric epithelial cells is critical. Decay-accelerating factor (DAF), a protein that protects epithelial cells from complement-mediated lysis, also functions as a receptor for several microbial pathogens. In this study, we investigated whether H. pylori utilizes DAF as a receptor and the role of DAF within H. pylori-infected gastric mucosa. In vitro studies showed that H. pylori adhered avidly to Chinese hamster ovary cells expressing human DAF but not to vector controls. In H. pylori, disruption of the virulence factors vacA, cagA, and cagE did not alter adherence, but deletion of DAF complement control protein (CCP) domains 1-4 or the heavily O-glycosylated serine-threonine-rich COOH-terminal domain reduced binding. In cultured gastric epithelial cells, H. pylori induced transcriptional up-regulation of DAF, and genetic deficiency of DAF attenuated the development of inflammation among H. pylori-infected mice. These results indicate that DAF may regulate H. pylori-epithelial cell interactions relevant to pathogenesis.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Helicobacter pylori induces an inflammatory response in the stomach that persists for decades and biological costs incurred by chronic infection include an increased risk for peptic ulceration, gastric adenocarcinoma, and non-Hodgkins lymphoma of the stomach (1, 2). However, most colonized individuals remain asymptomatic, and increased disease risk is related to bacterial strain differences, epithelial responses governed by host diversity, and/or specific interactions between host and microbial determinants.

While the vast majority of H. pylori in colonized hosts are free-living, ~20% bind to gastric epithelial cells, and this adherence is required for induction of injury. The H. pylori cag pathogenicity island encodes a type IV secretion system that, following adherence, translocates peptidoglycan and CagA into host cells (3-8). CagA subsequently undergoes Src-dependent tyrosine phosphorylation and activates a eukaryotic phosphatase (SHP-2), eventuating in dephosphorylation of host cell proteins and cellular morphological changes (6, 7, 9, 10). Recently, CagA has also been shown to activate beta-catenin and induce NF-{kappa}B-mediated interleukin-8 release from gastric epithelial cells (11, 12). The presence of the cag island influences the topography of colonization, as H. pylori cag- strains predominate within the mucus gel layer, while cag+strains are found immediately adjacent to epithelial cells (13). Concordant with these properties, H. pylori strains that harbor a functional cag island are associated with an increased risk for ulcer disease and gastric cancer compared with cag- strains (1).

Another H. pylori locus linked with pathologic outcomes is vacA, which encodes a bacterial toxin (VacA) that induces vacuolation and apoptosis of epithelial cells (14-16). VacA binds to a unique receptor-type protein-tyrosine phosphatase, PTP{zeta}, a member of a family of receptor-like enzymes that regulate cellular proliferation, differentiation, and adhesion (17). Another virulence factor, an adhesin termed BabA (encoded by the H. pylori strain-selective gene babA2), binds the blood group antigen Lewisb on gastric epithelial cell membranes (18, 52), and H. pylori babA2+strains increase the risk for gastric adenocarcinoma (19). Finally, genetic ablation of parietal cells in mice induces gastric epithelial progenitor cells to synthesize NeuAc{alpha}2,3Galbeta1,4 glycan, which serves as a receptor for H. pylori, and this is accompanied by an expansion of bacterial colonization and inflammation within the glandular epithelium (20, 21, 53). Collectively, these results indicate that dynamic and specific interactions between H. pylori and host receptors legislate pathologic outcome.

Decay-accelerating factor (DAF)2 is an intrinsic regulator of complement, which is attached to the outer leaflet of the cell membrane (22). It is a 70-kDa glycoprotein containing 4 contiguous 60-amino acid-long repeats termed complement control protein repeats (CCPs) followed by a serine-threonine-rich heavily O-glycosylated COOH-terminal domain that elevates the molecule at the membrane surface (22). DAF is membrane-linked by a glycosylphosphatidylinositol anchor. DAF protects self cells from complement activation on their surfaces by dissociating membrane-bound C3 convertases that are required for cleaving C3 and initiating further propagation of the complement cascade.

Previous work has shown that DAF is utilized as a cellular receptor for several pathogenic organisms including uropathogenic diffusely adhering Escherichia coli, coxsackieviruses, echoviruses, and enteroviruses (22-32). Studies by other investigators have shown that expression of DAF is increased within H. pylori-infected human gastric tissue compared with uninfected mucosa, and this increase is directly related to the density of H. pylori colonization and severity of inflammation (33-35). It has also been shown that increased DAF expression is present in gastric cancer precursor lesions such as intestinal metaplasia and gastric adenomas, and in gastric adenocarcinoma specimens compared with non-transformed gastric mucosa (36), suggesting that aberrant expression of DAF precedes the development of gastric cancer. Since DAF is overexpressed within H. pylori-associated premalignant and malignant lesions, we investigated whether H. pylori utilizes DAF as a receptor in vitro and the role of DAF within H. pylori-infected gastric mucosa to define a potential pathogenic response toward this organism.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Recombinant Cell Lines—Chinese hamster ovary (CHO) cell transfectant clones that stably express human DAF cDNA (DAF/A9), cDNA CCP deletion constructs (DAF{Delta}CCP1/029-6B, DAF{Delta}CCP2/043-7A, DAF{Delta}CCP3/044-2D, DAF{Delta}CCP4/054-5 x 4), a cDNA serine/threonine (S/T)-rich region deletion construct (DAF{Delta}S/T), a cDNA S/T region deletion construct containing an in-frame fusion of the cDNA encoding the amino-terminal region of DAF with the carboxyl terminus of HLA-B44 (DAF{Delta}S/T + HLA), or vector alone were used as described previously (37). Cells were cultured at 37 °C in Ham's nutrient mixture F-12 (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (Sigma), 50 units of penicillin/ml, 50 µg of streptomycin/ml, 2 mM L-glutamine, nonessential amino acids, and 250 µg of G418/ml when indicated. AGS (ATCC CRL 1739) or MKN28 (kindly provided by Dr. Robert Coffey, Vanderbilt University) human gastric epithelial cells were grown in RPMI 1640 (Invitrogen) with 10% heat-inactivated fetal bovine serum and 20 µg/ml gentamicin in an atmosphere of 5% CO2 at 37 °C.

Bacterial Strains Used in Vitro—Experiments were performed with the cag cag+ toxigenic H. pylori strain J166, as well as eight additional (5+ toxigenic, 3 cag- non-toxigenic) well characterized clinical strains. Clinical strains were selected from a larger population of isolates that have been previously described as part of an ongoing prospective study designed to study mechanisms of H. pylori pathogenesis (15). Since we sought to analyze the importance of H. pylori genes related to disease, we selected strains that varied in cag status and toxin production. Isogenic cagA, cagE, and vacA null mutants were constructed within strain J166 by insertional mutagenesis, using aphA (conferring kanamycin resistance) as described previously (15, 38), and were selected on Brucella agar with kanamycin (25 µg/ml). As bacterial controls, Campylobacter jejuni strain 81176 and a non-diffusely adhering flagellated E. coli strain (HB101) were also co-cultured with CHO cells (38).

Recombinant CHO cells expressing full-length DAF, its domain deletion mutants, or vector alone were seeded in 100-mm polypropylene tissue culture dishes (Nunc) at 2.5 x 106 cells/dish and allowed to grow for 24 h to subconfluence. H. pylori were grown in Brucella broth with 10% FCS for 18 h, harvested by centrifugation, resuspended to a concentration of 1 x 1010 colony forming units (cfu)/ml, and added to cells at a bacteria:cell ratio of 10:1 (39). Co-culture experiments with viable H. pylori were performed in antibiotic-free medium with 10% fetal bovine serum. For quantitative culture of adherent bacteria, H. pylori:CHO cell co-cultures were washed after 4 h with phosphate-buffered saline (PBS; pH 7.6) x 2 to remove non-adherent bacteria, and total cell extracts were harvested as described (38). Serial 10-fold dilutions of 1-ml aliquots of cell extracts were cultured on 5% sheep blood agar plates and incubated for 3-5 days under microaerobic conditions before H. pylori colonies were counted. Results are expressed as cfu/ml.

Immunofluorescence—CHO or gastric cells were cultured on glass cover slides, and cells treated with or without H. pylori for 4 h (multiplicity of infection = 100) were washed twice with PBS, fixed in 4% paraformaldehyde in PBS for 20 min at room temperature, incubated in 0.1% PBST (1x PBS, pH 7.6, 0.1% Tween 20) with 5% milk for 1 h, and then incubated with mouse monoclonal anti-DAF antibody 1H4 (1:100) (37) for 1 h. For dual immunofluorescence, slides were stained with mouse monoclonal anti-DAF antibody 1H4 (1:100) and rabbit anti-H. pylori antibody (1:100, DakoCytomation). Washed slides were then incubated with either goat anti-mouse Alexa Fluor 546-conjugated antibody (1:100; Molecular Probes) for single immunofluorescence or Alexa Fluor 488-conjugated goat anti-rabbit antibody and Alexa Fluor 546-conjugated goat anti-mouse antibody (1:100, Molecular Probes) for dual immunofluorescence at room temperature for 1 h. Nuclei were stained using 4',6-diamidino-2-phenylindole. Slides were mounted using Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and immunofluorescence was observed using a fluorescence microscope (40). For antibody inhibition studies, CHO cells were preincubated with anti-DAF monoclonal antibodies 11D7 (directed against CCP domain 1), 1H4 (directed against CCP domain 3), 8D11 (directed against CCP domain 4) (37), or ascites fluid containing the monoclonal antibody IF7 (directed against CCP domain 2) (25) for 30 min prior to infection with H. pylori.

Western Analysis—Transfected CHO cells or gastric cells from H. pylori:AGS or H. pylori:MKN28 cell co-cultures were lysed in RIPA buffer (50 mM Tris, pH 7.2, 150 mM NaCl, 1% Triton X-100, 0.1% SDS), and protein concentrations were quantified by the Bradford assay (Pierce) (38). Proteins (20 µg) were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Pall Corp., Ann Arbor, MI). DAF levels were measured in gastric cells by Western blotting using anti-DAF (1:1000, 1H4) antibodies (38). Primary antibodies were detected using goat anti-mouse (Santa Cruz Biotechnology) horseradish peroxidase-conjugated secondary antibodies and visualized by Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences) according to the manufacturer's instructions.

Real-time PCR—MKN28 and AGS gastric epithelial cells were grown to confluence, serum-starved for 24 h, and then co-cultured with H. pylori for 2, 6, 12, and 24 h (multiplicity of infection = 100). RNA was prepared from H. pylori:gastric cell co-cultures using TRIzol Reagent following the manufacturer's instructions (Invitrogen), and contaminating DNA was removed using the RNeasy RNA purification kit (Qiagen). Reverse transcriptase PCR was performed using TaqMan reverse transcription reagents (Applied Biosystems), which was followed by real-time quantitative PCR using the TaqMan gene expression assay and a 7300 real-time PCR system (Applied Biosystems). DAF cDNA was quantitated using a DAF TaqMan gene expressions primer set purchased from Applied Biosystems and expression levels were normalized to levels of 18 S rRNA.

Mice, Bacteria, and Experimental Infections—Daf1 knock-out mice were developed as described previously (41). Briefly, the Daf1 gene on one chromosome was inactivated by homologous recombination and Cre/LoxP-mediated deletion in murine GK129 embryonic stem cells. The recombined embryonic stem cells were microinjected into blastocytes, chimeras were generated, and the chimeric mice were then bred with the C57BL/6 strain. Eight- to 12-week knock-out mice and wild-type C57BL/6 mice were used. All experiments were approved by the Case Western Reserve Institutional Animal Care and Use Committee. Brucella broth containing 2 x 107 cfu of the H. pylori rodent-adapted strain SS1 was used as inoculum and was delivered by gastric intubation as described previously (42).


Figure 1
View larger version (62K):
[in this window]
[in a new window]
  		FIGURE 1.
H. pylori strain J166 adheres significantly more avidly to CHO cells expressing full-length human DAF. A, Western blot for human DAF using CHO cells transfected with either full-length human DAF or vector alone. B, CHO cells transfected with either full-length DAF (DAF+) or vector alone (DAF-) were incubated with H. pylori strain J166, E. coli strain HB101, or C. jejuni strain 81176 (10:1 bacteria:epithelial cell ratio). Bacterial adherence was assessed using quantitative culture as described under "Materials and Methods." Error bars, S.E.; *, p < 0.05 versus infected DAF- cells. C, distribution of H. pylori (green) and DAF (red) in CHO cells transfected with either full-length human DAF or vector alone was detected by immunofluorescence as described under "Materials and Methods."

 
Eight weeks post-challenge, mice were euthanized. At necropsy, linear strips extending from the squamocolumnar junction through proximal duodenum were fixed in 10% neutral buffered formalin, paraffin-embedded, cut at 5 µm, and stained with hematoxylin and eosin. Indices of inflammation and injury in the gastric cardia, corpus, and antrum were scored on an ordinal scale from 0 to 5 in increments of 0.5 by a single veterinary pathologist blinded to treatment groups as described previously (42).

For quantitative culture, gastric tissue was homogenized, plated, and incubated under microaerobic conditions at 37 °C for 5-6 days as described previously (42). After verification by Gram's stain, urease, catalase, and oxidase reactions, colonies were counted and comparisons between groups were based on the log cfu/gram of stomach tissue as described (42).

Statistical Analysis—The Mann-Whitney U test was used for statistical analyses of intergroup comparisons. Significance was defined as p ≤ 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of Human DAF Increases Cellular Binding of H. pylori in Vitro—To determine whether DAF mediates H. pylori binding to host cells, we used CHO cells stably transfected with a human DAF cDNA or vector alone (Fig. 1A) and co-cultured the transfectants with a well characterized H. pylori strain, J166, which is easily transformable and binds well to gastric epithelial cells (15, 43). We assessed binding by quantitative culture. Compared with cells lacking DAF, H. pylori strain J166 bound more avidly to DAF-expressing cells and recoverable colony-forming units were >1 log-fold higher following only 4 h of co-culture (Fig. 1B).


Figure 2
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 2.
Adherence of H. pylori to DAF-expressing cells is not mediated by the cag pathogenicity island or vacA. A, CHO cells transfected with either full-length DAF (DAF+) or vector alone (DAF-) were cultured in the presence of the wild-type (wt) H. pylori cag+ toxigenic strain J166 or isogenic cagA, cagE,or vacA null mutant derivatives at bacteria:cell ratios of 10:1. Adherence was assessed by quantitative culture. Error bars, S.E.; *, p < 0.05 versus infected DAF- cells. B, adherence to DAF+ or DAF- CHO cells by H. pylori clinical isolates with varying cag island status and toxigenic phenotypes was assessed using quantitative culture. Results are expressed as a ratio of H. pylori recovered from DAF+ versus DAF- cells. A representative result of multiple repetitions performed on at least two occasions is shown.

 
To further assess DAF binding by H. pylori, we used immunofluorescence. For this, strain J166 was co-cultured with CHO cells that either did or did not express DAF. A significantly greater number of H. pylori adhered to DAF+versus DAF- CHO cells (Fig. 1C).

To ensure that H. pylori binding to DAF was a specific interaction rather than a nonspecific bacterial response of the cells to bacteria, we incubated DAF- CHO cells with equivalent numbers of non-diffusely adhering E. coli or C. jejuni for 4 h and measured binding by quantitative culture. Adherence of E. coli or C. jejuni did not differ between CHO cells that either expressed or did not express DAF (Fig. 1B). Thus, the DAF interaction specifically mediated adherence of H. pylori to host cells.

Binding to DAF Is Independent of H. pylori Virulence Constituents Encoded by the cag Pathogenicity Island or vacA—The H. pylori cag island and vacA induce epithelial responses that may lower the threshold for disease. Consequently, we examined the effects of these virulence determinants on binding of H. pylori to DAF-expressing cells. To do this, we co-cultured DAF+ and DAF+ or DAF- CHO cells with H. pylori wild-type cag+ toxigenic strain J166 or isogenic cagA, cagE, or vacA null mutant derivatives. Compared with the parental wild-type strain, loss of cagA had no effect on binding to DAF (Fig. 2A). Inactivation of cagE or vacA decreased the extent of bacterial binding compared with the wild-type strain; however, the level of reduction was similar in DAF-expressing and DAF-deficient CHO cells (Fig. 2A). These results indicate that, although cagE and vacA may contribute to binding of H. pylori to host cells, these effects do not involve DAF.


Figure 3
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 3.
Adherence of H. pylori to DAF-expressing cells is mediated by multiple DAF domains. A, H. pylori strain J166 was co-cultured with CHO cells stably transfected with either full-length human DAF (wild-type (WT)), a series of deletion mutants that individually lack one of the four DAF CCP domains, a S/T-rich region deletion mutant ({Delta}S/T), a S/T-rich region deletion mutant containing an in-frame fusion of the cDNA encoding the amino-terminal region of DAF with the carboxyl terminus of HLA-B44 ({Delta}S/T + HLA), or vector alone. Bacterial adherence was assessed using quantitative culture as described under "Materials and Methods" and is expressed as a ratio of H. pylori recovered from DAF+ versus DAF- cells. Therefore, a value of 1 represents base line. Error bars, S.E.; *, p < 0.05 versus infected DAF- cells. B, binding of H. pylori to CHO cells transfected with either vector alone (DAF-) or full-length human DAF (DAF+) in the presence or absence of an equal mixture of anti-DAF CCP-specific monoclonal antibodies 11D7, IF7, 1H4, or 8D11, or an irrelevant anti-Myc monoclonal antibody was detected by immunofluorescence as described under "Materials and Methods." Error bars, S.E.; *, p < 0.05 versus infected DAF- cells.

 
The Extent of H. pylori Binding to DAF-expressing Cells Varies among a Population of Clinical Isolates—Most persons infected with H. pylori cag+toxigenic strains remain asymptomatic, suggesting that additional microbial and/or host factors influence disease. Therefore, we next investigated DAF binding patterns among a population of clinical H. pylori isolates. Although absolute levels varied between different isolates, all nine strains tested (6 cag- non-toxigenic) displayed at least a 10-fold increase in binding affinity to DAF DAF+ toxigenic, 3 cag+ versus- CHO cells (Fig. 2B). Levels of binding did not segregate with cag genotype or toxigenicity, confirming the results from isogenic mutant experiments (Fig. 2A).

Binding of H. pylori to CHO Cells That Express Mutant DAF—DAF is composed of four CCPs, and microbial pathogens vary in their utilization of CCP domains for binding. Based on this, we next localized the sites on DAF that H. pylori utilize by studying CHO cells stably transfected with deletion mutants of each of the four DAF CCP domains. Each deletion mutant expresses an amount of DAF at least equal to cells expressing wild-type DAF (37). Removal of CCP domains 1, 2 or 3 completely abolished H. pylori binding to DAF (Fig. 3A), whereas removal of CCP4, the domain in closest apposition to the cell surface, resulted in an approximate 60-70% reduction in binding.


Figure 4
View larger version (61K):
[in this window]
[in a new window]
  		FIGURE 4.
H. pylori strain J166 up-regulates DAF in gastric epithelial cells. A, MKN28 gastric epithelial cells were cultured for 24 h prior to incubation with H. pylori strain J166. Levels of DAF mRNA were determined by real-time RT-PCR as described under "Materials and Methods" and were normalized to corresponding levels of 18 S rRNA. Results are expressed as fold increase in DAF mRNA in H. pylori-infected versus uninfected samples. Error bars, S.E.; *, p < 0.05 versus uninfected cells at corresponding time point. B, MKN28 cells were cultured for 24 h prior to incubation with H. pylori strain J166. Cell extracts harvested at different time points were then used for Western blot analysis using an anti-DAF antibody as described under "Materials and Methods." -, cells incubated with medium alone. A representative blot of multiple repetitions performed on at least three occasions is shown. Anti-actin blots served as normalization controls for MKN28 cell viability under different experimental conditions. C, distribution of DAF (red) in MKN28 gastric epithelial cells was detected by immunofluorescence following infection with medium alone (left panel) or H. pylori strain J166 (right panel) for 24 h.

 
To further confirm the role of CCP domains for H. pylori binding, DAF- CHO cells were pretreated with the DAF CCP-specific monoclonal antibodies 11D7, IF7, IH4, and 8D11 prior to infection with H. pylori strain J166. Preincubation with each individual monoclonal antibody alone did not significantly reduce H. pylori binding to DAF+ and DAF+ cells (data not shown). However, preincubation with an equal mixture of the four CCP domain-specific monoclonal antibodies completely blocked adherence of H. pylori to DAF-expressing cells (Fig. 3B), confirming the results using cells transfected with DAF CCP deletion mutants (Fig. 3A).

DAF CCP domains are linked to a S/T-rich heavily O-glycosylated COOH-terminal domain that elevates the molecule at the membrane surface. Since H. pylori can bind to carbohydrate residues on cell surfaces (1, 2), we determined the requirement for the DAF S/T region by utilizing a CHO cell transfectant clone that stably expresses a DAF cDNA construct containing a deletion of the S/T-rich domain or a clone expressing a S/T deletion construct that attaches the four CCP domains to the unrelated non-complement protein HLA-B44. The latter construct is anchored by the transmembrane and cytoplasmic domains of HLA-B44 and functions efficiently as a complement regulatory protein. Results from binding experiments using both of these S/T-deficient DAF clones demonstrate that removal of the O-glycosylated region decreased H. pylori binding to DAF (Fig. 3A), indicating that the S/T region does not simply function as a nonspecific spacer for binding. These results indicate that H. pylori binding to DAF either involves all CCP domains or is dependent on the conformation of DAF in its intact state.

H. pylori Induces DAF Expression in Human Gastric Epithelial Cells— Since H. pylori is a human pathogen that selectively colonizes gastric epithelium, we investigated whether H. pylori alters DAF expression in human gastric epithelial cells. Real-time PCR analysis demonstrated that H. pylori induced DAF expression in MKN28 (Fig. 4A) and AGS (data not shown) gastric epithelial cells beginning at 2 h. Levels decreased to base line by 24 h post-inoculation. H. pylori co-culture mRNA changes reflected increased DAF protein expression, since increases in levels were detected at 6 h and DAF protein remained elevated for 24 h (Fig. 4B). Immunofluorescence staining confirmed the increased DAF expression on MKN28 gastric epithelial cells following co-culture with H. pylori (Fig. 4C). These results indicate that the prototype H. pylori strain J166 induces transcriptional up-regulation of DAF in human gastric epithelial cells.

H. pylori-induced Gastric Inflammation Is Attenuated in the Absence of DAF—To determine whether the DAF binding is physiologically relevant within the context of H. pylori-induced inflammation in vivo, we utilized Daf1-/- mice and the rodent-adapted H. pylori strain SS1. We infected wild-type and Daf1-/- mice in two independent challenges and followed disease outcome. All mice challenged with H. pylori were successfully infected and there were no differences in colonization efficiency or density between wild-type and DAF deficient mice (Fig. 5A).


Figure 5
View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 5.
DAF deficiency significantly attenuates inflammation, but not colonization density, in H. pylori-infected mice. A, wild-type (WT) or Daf1-/- littermates were infected with H. pylori strain SS1 for 8 weeks in two independent experiments. Colonization density was determined by quantitative culture as described under "Materials and Methods," and results are expressed as log cfu/gram of stomach tissue. Error bars, S.E. B, comparison of gastric inflammation in wild-type (WT) or Daf1-/- mice infected with H. pylori strain SS1 or broth alone. Mucosal inflammation was determined by histologic testing, as described under "Materials and Methods," and scores are expressed as scatter plots with mean values. *, p = 0.013 versus H. pylori-infected Daf1-/- mice.

 
Eight weeks post-challenge, there were few lesions in the stomachs of wild-type or Daf1-/- mice inoculated with broth alone (Fig. 5B), whereas, as expected, wild-type mice challenged with H. pylori developed gastritis. Inflammation was most extensive at the transition zones between the antrum or cardia and the corpus. Inflammatory cells within infected mucosa consisted of polymorphonuclear cells and large mononuclear cells in the lamina propria (Fig. 6). In the lamina propria, the infiltrate separated and displaced the glands (Fig. 6). Gastric pits were lengthened and were lined by less mature flattened epithelial cells with basophilic cytoplasm; mitotic figures were frequently identified. In the submucosa, edema often accompanied the cellular infiltrate (Fig. 6).

In contrast to infected wild-type mice, in H. pylori-colonized DAF-deficient mice, the intensity of inflammation was significantly attenuated (p = 0.013) (Figs. 5B and 6). Moreover, there were no differences in severity of gastritis between uninfected and infected Daf1-/- mice (p = 0.53; Fig. 5B). These results thus indicate that DAF contributes to the ability of H. pylori to induce injury within the gastric niche.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Colonization of humans by pathogenic bacteria is common, but disease occurs in only a fraction of infected persons. Our current experiments identify a new mechanism that may contribute to H. pylori pathogenesis. This insight was gained by 1) capitalizing on a recombinant cell model to demonstrate that the protein DAF serves as a receptor for H. pylori, 2) finding that H. pylori can induce DAF expression in a biologically relevant in vitro model of microbial:gastric epithelial cell interaction, 3) both confirming and mapping the components of DAF required for these effects, and 4) through the use of a Daf1-/- knock-out mouse, documenting that the interaction is important for pathogenesis. Collectively, these studies indicate that H. pylori co-opts DAF as a receptor to induce disease.


Figure 6
View larger version (98K):
[in this window]
[in a new window]
  		FIGURE 6.
Development of inflammation and injury within the gastric corpus of H. pylori-infected wild-type (WT), but not Daf1-/- mice, 8 weeks post-inoculation. Representative hematoxylin and eosin stains are shown (original magnification: x40). Mild to moderate inflammation is present within the lamina propria of H. pylori-infected wild-type mice (left panel, arrows). In contrast, no significant inflammation or injury is present within gastric mucosa of H. pylori-infected Daf1-/- mice (right panel).

 
The hallmark of the gastric inflammatory response to H. pylori is its capacity to persist for decades. This is in contrast to inflammatory reactions induced by other mucosal pathogens, such as Salmonella, that either resolve within days or progress to eliminate the host. Research to date has shown that H. pylori has evolved numerous strategies to facilitate its persistence within the stomach including limiting the bactericidal effects of pro-inflammatory molecules (44) and varying the antigenic repertoire of surface-exposed proteins (45). Adherence of H. pylori to gastric epithelial cells is also critical for colonization. According to our data, the ability of H. pylori to utilize DAF as a receptor contributes to the latter strategy and is consistent with the role that this molecule plays in other host-microbial interactions involving persistent pathogens. E. coli that express DAF-binding Dr adhesins cause chronic interstitial nephritis (46). Echoviruses and coxsackieviruses that target DAF as a receptor are associated with chronic fatigue syndrome and chronic dilated cardiomyopathy, respectively (47, 48). The current studies focused on H. pylori-DAF interactions further implicate DAF as a receptor that is exploited by pathogens notable for their ability to induce chronic inflammation, injury, and disease.

Our in vitro results indicate that binding of DAF by H. pylori requires all of the CCP domains and the S/T-rich O-glycosylated region, a pattern that is distinct from those involved in DAF binding by other pathogens. For example, Dr-expressing E. coli require CCP2 and CCP3 (23-25). E. coli that express X adhesins require CCP3 and CCP4 (26). Echovirus 7 utilizes CCPs 2-4 (27, 28), and coxsackieviruses A21 and B3 exploit CCP1 and CCP2, respectively (29-31). Another layer of complexity beyond the scope of this investigation is added when results from inhibition studies are considered. Anti-DAF antibodies that block cellular binding of coxsackievirus 21 reciprocally enhance binding of echovirus 7 (32), raising the possibility that ligand binding of one CCP domain affects binding of another CCP moiety within the same DAF molecule. Importantly, we have a unique in vitro model of bacteria-epithelia interactions using an H. pylori strain that is easily transformable in which to evaluate the individual and collective effects of each of these factors.

Murine models have provided valuable insights into the host, bacterial, and environmental factors involved in H. pylori-induced gastric inflammation and injury. Using a Daf1-/- mouse, we now demonstrate that loss of DAF does not alter colonization but attenuates the inflammatory response to H. pylori. This may occur via more than one mechanism. Our available data so far indicate that H. pylori up-regulates DAF in gastric epithelial cells. This is consistent with reports from other investigators that DAF expression is increased within infected human gastric mucosa, where it localizes to the apical surface of gastric epithelial cells (33-35). One possibility raised by our findings is that in addition to direct bacterial stimulation, expression of DAF can be increased by H. pylori-induced pro-inflammatory cytokines such as interleukin-1beta and tumor necrosis factor-{alpha}, which are up-regulated in response to transepithelial migration of neutrophils (49, 50). DAF has also been recently identified as an apical epithelial ligand for polymorphonuclear cells that regulates the rate of neutrophil migration across apical epithelial membranes (51). Finally, since H. pylori binding to DAF involves its complement regulatory CCP2 and CCP3 domains, the binding might affect complement activation. All these questions will require further study. Thus, DAF regulated by both H. pylori and host immune mediators is well positioned to modulate the inflammatory response to this pathogen.

In conclusion, H. pylori binds avidly to cells expressing human DAF and this is mediated by DAF CCPs 1-4 and the O-glycosylated serine-threonine-rich COOH-terminal domain. H. pylori induces transcriptional up-regulation of DAF in gastric epithelial cells, and in vivo DAF deficiency decreases the intensity of inflammation in H. pylori-infected mice. Taken together, these data open a new avenue of investigation in pathogenic mechanisms underlying H. pylori infection.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grants DK-58587 and CA-77955 (to R. M. P.) and by the Medical Research Service of the Department of Veterans Affairs (to R. M. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{diamondsuit} This article was selected as a Paper of the Week. Back

1 To whom correspondence should be addressed: Division of Gastroenterology, Vanderbilt University School of Medicine, 2215 Garland Ave., 1030C MRB IV, Nashville, TN 37232-2279. Tel.: 615-322-5200; Fax: 615-343-6229; E-mail: richard.peek{at}vanderbilt.edu.

2 The abbreviations used are: DAF, decay-accelerating factor; CCP, complement control protein; CHO, Chinese hamster ovary; S/T, serine-threonine; cfu, colony forming units; PBS, phosphate-buffered saline. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Peek, R. M., Jr., and Blaser, M. J. (2002) Nat. Rev. Cancer 2, 28-37[CrossRef][Medline] [Order article via Infotrieve]
  2. Moss, S. F., and Sood, S. (2003) Curr. Opin. Infect. Dis. 16, 445-451[CrossRef][Medline] [Order article via Infotrieve]
  3. Odenbreit, S., Puls, J., Sedlmaier, B., Gerland, E., Fischer, W., and Haas, R. (2000) Science 287, 1497-1500[Abstract/Free Full Text]
  4. Stein, M., Rappuoli, R., and Covacci, A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 1263-1268[Abstract/Free Full Text]
  5. Asahi, M., Azuma, T., Ito, S., Ito, Y., Suto, H., Nagai, Y., Tsubokawa, M., Tohyama, Y., Maeda, S., Omata, M., Suzuki, T., and Sasakawa, C. (2000) J. Exp. Med. 191, 593-602[Abstract/Free Full Text]
  6. Backert, S., Ziska, E., Brinkmann, V., Zimny-Arndt, U., Fauconnier, A., Jungblut, P. R., Naumann, M., and Meyer, T. F. (2000) Cell Microbiol. 2, 155-164[CrossRef][Medline] [Order article via Infotrieve]
  7. Selbach, M., Moese, S., Hauck, C. R., Meyer, T. F., and Backert, S. (2002) J. Biol. Chem. 277, 6775-6778[Abstract/Free Full Text]
  8. Viala, J., Chaput, C., Boneca, I. G., Cardona, A., Girardin, S. E., Moran, A. P., Athman, R., Memet, S., Huerre, M. R., Coyle, A. J., Distefano, P. S., Sansonetti, P. J., Labigne, A., Bertin, J., Philpott, D. J., and Ferrero, R. L. (2004) Nat. Immunol. 5, 1166-1174[CrossRef][Medline] [Order article via Infotrieve]
  9. Stein, M., Bagnoli, F., Halenbeck, R., Rappuoli, R., Fantl, W. J., and Covacci, A. (2002) Mol. Microbiol. 43, 971-980[CrossRef][Medline] [Order article via Infotrieve]
  10. Higashi, H., Tsutsumi, R., Muto, S., Sugiyama, T., Azuma, T., Asaka, M., and Hatakeyama, M. (2002) Science 295, 683-686[Abstract/Free Full Text]
  11. Brandt, S., Kwok, T., Hartig, R., Konig, W., and Backert, S. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 9300-9305[Abstract/Free Full Text]
  12. Franco, A. T., Israel, D. A., Washington, M. K., Krishna, U., Fox, J. G., Rogers, A. B., Neish, A. S., Collier-Hyams, L., Perez-Perez, G. I., Hatakeyama, M., Whitehead, R., Gaus, K., O'Brien D, P., Romero-Gallo, J., and Peek, R. M., Jr. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10646-10651[Abstract/Free Full Text]
  13. Camorlinga-Ponce, M., Romo, C., Gonzalez-Valencia, G., Munoz, O., and Torres, J. (2004) J. Clin. Pathol. 57, 822-828[Abstract/Free Full Text]
  14. Leunk, R. D., Johnson, P. T., David, B. C., Kraft, W. G., and Morgan, D. R. (1988) J. Med. Microbiol. 26, 93-99[Abstract/Free Full Text]
  15. Peek, R. M., Jr., Blaser, M. J., Mays, D. J., Forsyth, M. H., Cover, T. L., Song, S. Y., Krishna, U., and Pietenpol, J. A. (1999) Cancer Res. 59, 6124-6131[Abstract/Free Full Text]
  16. Cover, T. L., Krishna, U. S., Israel, D. A., and Peek, R. M., Jr. (2003) Cancer Res. 63, 951-957[Abstract/Free Full Text]
  17. Fujikawa, A., Shirasaka, D., Yamamoto, S., Ota, H., Yahiro, K., Fukada, M., Shintani, T., Wada, A., Aoyama, N., Hirayama, T., Fukamachi, H., and Noda, M. (2003) Nat. Genet. 33, 375-381[CrossRef][Medline] [Order article via Infotrieve]
  18. Solnick, J. V., Hansen, L. M., Salama, N. R., Boonjakuakul, J. K., and Syvanen, M. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 2106-2111[Abstract/Free Full Text]
  19. Gerhard, M., Lehn, N., Neumayer, N., Boren, T., Rad, R., Schepp, W., Miehlke, S., Classen, M., and Prinz, C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12778-12783[Abstract/Free Full Text]
  20. Syder, A. J., Oh, J. D., Guruge, J. L., O'Donnell, D., Karlsson, M., Mills, J. C., Bjorkholm, B. M., and Gordon, J. I. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 3467-3472[Abstract/Free Full Text]
  21. Oh, J. D., Karam, S. M., and Gordon, J. I. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 5186-5191[Abstract/Free Full Text]
  22. Servin, A. L. (2005) Clin. Microbiol. Rev. 18, 264-292[Abstract/Free Full Text]
  23. Nowicki, B., Hart, A., Coyne, K. E., Lublin, D. M., and Nowicki, S. (1993) J. Exp. Med. 178, 2115-2121[Abstract/Free Full Text]
  24. Hasan, R. J., Pawelczyk, E., Urvil, P. T., Venkatarajan, M. S., Goluszko, P., Kur, J., Selvarangan, R., Nowicki, S., Braun, W. A., and Nowicki, B. J. (2002) Infect. Immun. 70, 4485-4493[Abstract/Free Full Text]
  25. Guignot, J., Peiffer, I., Bernet-Camard, M. F., Lublin, D. M., Carnoy, C., Moseley, S. L., and Servin, A. L. (2000) Infect. Immun. 68, 3554-3563[Abstract/Free Full Text]
  26. Pham, T., Kaul, A., Hart, A., Goluszko, P., Moulds, J., Nowicki, S., Lublin, D. M., and Nowicki, B. J. (1995) Infect. Immun. 63, 1663-1668[Abstract]
  27. Clarkson, N. A., Kaufman, R., Lublin, D. M., Ward, T., Pipkin, P. A., Minor, P. D., Evans, D. J., and Almond, J. W. (1995) J. Virol. 69, 5497-5501[Abstract]
  28. He, Y., Lin, F., Chipman, P. R., Bator, C. M., Baker, T. S., Shoham, M., Kuhn, R. J., Medof, M. E., and Rossmann, M. G. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10325-10329[Abstract/Free Full Text]
  29. Karnauchow, T. M., Dawe, S., Lublin, D. M., and Dimock, K. (1998) J. Virol. 72, 9380-9383[Abstract/Free Full Text]
  30. Shafren, D. R., Dorahy, D. J., Thorne, R. F., Kinoshita, T., Barry, R. D., and Burns, G. F. (1998) J. Immunol. 160, 2318-2323[Abstract/Free Full Text]
  31. Bergelson, J. M., Mohanty, J. G., Crowell, R. L., St John, N. F., Lublin, D. M., and Finberg, R. W. (1995) J. Virol. 69, 1903-1906[Abstract]
  32. Shafren, D. R. (1998) J. Virol. 72, 9407-9412[Abstract/Free Full Text]
  33. Sasaki, M., Joh, T., Tada, T., Okada, N., Yokoyama, Y., and Itoh, M. (1998) Histopathology 33, 554-560[CrossRef][Medline] [Order article via Infotrieve]
  34. Berstad, A. E., and Brandtzaeg, P. (1998) Gut 42, 522-529[Abstract/Free Full Text]
  35. Rautemaa, R., Rautelin, H., Puolakkainen, P., Kokkola, A., Karkkainen, P., and Meri, S. (2001) Gastroenterology 120, 470-479[CrossRef][Medline] [Order article via Infotrieve]
  36. Kiso, T., Mizuno, M., Nasu, J., Shimo, K., Uesu, T., Yamamoto, K., Okada, H., Fujita, T., and Tsuji, T. (2002) Histopathology 40, 339-347[CrossRef][Medline] [Order article via Infotrieve]
  37. Coyne, K. E., Hall, S. E., Thompson, S., Arce, M. A., Kinoshita, T., Fujita, T., Anstee, D. J., Rosse, W., and Lublin, D. M. (1992) J. Immunol. 149, 2906-2913[Abstract]
  38. Crawford, H. C., Krishna, U. S., Israel, D. A., Matrisian, L. M., Washington, M. K., and Peek, R. M., Jr. (2003) Gastroenterology 125, 1125-1136[CrossRef][Medline] [Order article via Infotrieve]
  39. Israel, D. A., Salama, N., Arnold, C. N., Moss, S. F., Ando, T., Wirth, H. P., Tham, K. T., Camorlinga, M., Blaser, M. J., Falkow, S., and Peek, R. M., Jr. (2001) J. Clin. Invest. 107, 611-620[CrossRef][Medline] [Order article via Infotrieve]
  40. Gupta, R. A., Polk, D. B., Krishna, U., Israel, D. A., Yan, F., DuBois, R. N., and Peek, R. M., Jr. (2001) J. Biol. Chem. 276, 31059-31066[Abstract/Free Full Text]
  41. Lin, F., Fukuoka, Y., Spicer, A., Ohta, R., Okada, N., Harris, C. L., Emancipator, S. N., and Medof, M. E. (2001) Immunology 104, 215-225[CrossRef][Medline] [Order article via Infotrieve]
  42. Garhart, C. A., Redline, R. W., Nedrud, J. G., and Czinn, S. J. (2002) Infect. Immun. 70, 3529-3538[Abstract/Free Full Text]
  43. Peek, R. M., Jr., Thompson, S. A., Donahue, J. P., Tham, K. T., Atherton, J. C., Blaser, M. J., and Miller, G. G. (1998) Proc. Assoc. Am. Physicians 110, 531-544[Medline] [Order article via Infotrieve]
  44. Gobert, A. P., McGee, D. J., Akhtar, M., Mendz, G. L., Newton, J. C., Cheng, Y., Mobley, H. L., and Wilson, K. T. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13844-13849[Abstract/Free Full Text]
  45. Aras, R. A., Fischer, W., Perez-Perez, G. I., Crosatti, M., Ando, T., Haas, R., and Blaser, M. J. (2003) J. Exp. Med. 198, 1349-1360[Abstract/Free Full Text]
  46. Selvarangan, R., Goluszko, P., Popov, V., Singhal, J., Pham, T., Lublin, D. M., Nowicki, S., and Nowicki, B. (2000) Infect. Immun. 68, 1391-1399[Abstract/Free Full Text]
  47. Yousef, G. E., Bell, E. J., Mann, G. F., Murugesan, V., Smith, D. G., McCartney, R. A., and Mowbray, J. F. (1988) Lancet 1, 146-150[CrossRef][Medline] [Order article via Infotrieve]
  48. Martino, T. A., Liu, P., and Sole, M. J. (1994) Circ. Res. 74, 182-188[Abstract/Free Full Text]
  49. Betis, F., Brest, P., Hofman, V., Guignot, J., Kansau, I., Rossi, B., Servin, A., and Hofman, P. (2003) Infect. Immun. 71, 1774-1783[Abstract/Free Full Text]
  50. Betis, F., Brest, P., Hofman, V., Guignot, J., Bernet-Camard, M. F., Rossi, B., Servin, A., and Hofman, P. (2003) Infect. Immun. 71, 1068-1074[Abstract/Free Full Text]
  51. Lawrence, D. W., Bruyninckx, W. J., Louis, N. A., Lublin, D. M., Stahl, G. L., Parkos, C. A., and Colgan, S. P. (2003) J. Exp. Med. 198, 999-1010[Abstract/Free Full Text]
  52. Ilver, D., Arnqvist, A., Ogren, J., Frick, I. M., Kersulyte, D., Incecik, E. T., Berg, D. E., Covacci, A., Engstrand, L., and Boren, T. (1998) Science 279 373-377[Abstract/Free Full Text]
  53. Mahdavi, J., Sonden, B., Hurtig, M., Olfat, F. O., Forsberg, L., Roche, N., Angstrom, J., Larsson, T., Teneberg, S., Karlsson, K. A., Altraja, S., Wadstrom, T., Kersulyte, D., Berg, D. E., Dubois, A., Petersson, C., Magnusson, K. E., Norberg, T., Lindh, F., Lundskog, B. B., Arnqvist, A., Hammarstrom, L., and Boren T. (2002) Science 297, 573-578[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
D. P. O'Brien, J. Romero-Gallo, B. G. Schneider, R. Chaturvedi, A. Delgado, E. J. Harris, U. Krishna, S. R. Ogden, D. A. Israel, K. T. Wilson, et al.
Regulation of the Helicobacter pylori Cellular Receptor Decay-accelerating Factor
J. Biol. Chem., August 29, 2008; 283(35): 23922 - 23930.
[Abstract] [Full Text] [PDF]

Home page
 DMMHome page
R. M. Peek Jr
Helicobacter pylori infection and disease: from humans to animal models
Dis. Model. Mech., July 1, 2008; 1(1): 50 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in GastroenterologyHome page
R. M. Peek Jr
Review: Prevention of gastric cancer: When is treatment of Helicobacter pylori warranted?
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 19 - 31.
[Abstract] [PDF]

Home page
 BloodHome page
X. Zhang, Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J. D. Lambris, R. A. Wetsel, T. Miwa, and W.-C. Song
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo
Blood, July 1, 2007; 110(1): 228 - 236.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/19/13317    most recent
M601805200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, D. P.
Right arrow Articles by Peek, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, D. P.
Right arrow Articles by Peek, R. M., Jr.
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement